<DOC>
	<DOC>NCT00698269</DOC>
	<brief_summary>This study is conducted in Asia. The aim of this observational study is to evaluate the safety and efficacy of modern insulins after switch from any other anti-diabetic treatment under normal clinical conditions in the Gulf countries.</brief_summary>
	<brief_title>An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 1 or type 2 diabetes Treatment with any diabetes treatment other than NovoMix® 30, Levemir® and/or NovoRapid® Selection will be at the discretion of the individual physician Current treatment with Levemir®, NovoMix® 30 and/or NovoRapid® Previous enrolled in this study Hypersensitivity to Levemir®, NovoMix® 30 and/or NovoRapid® or to any of the excipients Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 6 months</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>